ESMO Asia
Nov 25, 2022
ESMO Asia 2022: Role of EGFR and ALK mutations in the East Asian Lung Cancer Market
Lung Cancer presents a heavy health and economic burden in Asia, being the most common form of cancer, with 60% of the world’s lung cancers being diagnosed there. Lung cancer is also present in more than 30% of non-smokers in Asia, specifically in adenocarcinomas, which is a subtype largely defined by oncogenic dri...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
